1911P - Implementation of remote patient monitoring in thoracic oncology: A real-world experience from 489 pts across 41 centers in France

Background

Remote patient monitoring (RPM) using electronic Patient Reported Outcomes (ePROs) offers a unique opportunity to early detect actionable symptoms commonly experienced by patients undergoing anticancer therapy. RPM demonstrated effectiveness in reducing morbidity, while improving quality of life through multiple phase III trials. Therefore, the European Society for Medical Oncology (ESMO) recommended the use of RPM based on ePROs in routine care in the 2022 clinical practice guidelines. However, its application in thoracic oncology remains largely unknown.

Methods

The RPM pathway includes four steps: (i) medical prescription, (ii) patients onboarding by a nurse, (iii) weekly collection of tailored symptoms survey (iv) severe (grades 3-4) or worsening symptoms (moving from a grade 0 to 2) trigger an alert notification to the care team. Data from all patients treated for lung malignancies and included in the RPM solution between January 2022 and January 2024 were analyzed.

Results

A total of 489 patients (43% female) were included across 41 healthcare centers in France (mean age 67, range (25 - 92). Primary tumor types were NSCLC (86%), SCLC (12%), and Mesothelioma (2%). Disease status was localized in 49% and advanced/metastatic in 51%. Systemic treatments included chemotherapy (50%), immunotherapy (39%), and targeted therapy (11%). At 3 months, 84% of patients adhered to the weekly questionnaires. The most frequent grade ≥3 symptoms were pain (56%), dyspnea (38%), diarrhea (34%). After the alerts, the assessment of symptoms within two weeks showed a proportion of 96% with at least 1 grade improvement and 81% showing an improvement of 2 to 3 grade points from the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) measurement system.

Conclusions

The implementation of an RPM pathway into routine care for patients with thoracic malignancies demonstrates feasibility with high adherence rate. These findings suggest a benefit of integrating RPM in thoracic oncology as a standard of care in routine clinical practice.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Resilience.

Funding

Has not received any funding.

Disclosure

L. Greillier: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, BMS, MSD, Novartis, Sanofi, Takeda, Roche; Financial Interests, Personal, Invited Speaker: Lilly, Pfizer; Financial Interests, Institutional, Local PI: AstraZeneca, AbbVie, BMS, MSD, Novartis, Takeda, Pfizer, Roche, PharmaMar; Financial Interests, Institutional, Coordinating PI: Sanofi. B. Besse: Financial Interests, Institutional, Advisory Board: Amgen, AstraZeneca, beigene, Blueprint Medicine, Cergentis, Chugai pharmaceutical, Daiichi Sankyo, F. Hoffmann-La Roche, Inivata, Pfizer, PharmaMar, Sanofi Aventis, Springer Healthcare Ltd, 4D Pharma, AbbVie, Da Voltera, Eli Lilly, Ellipse pharma Ltd, F-Star, GSK, Janssen, Onxeo, Ose Immunotherapeutics, Socar research, Taiho oncology, Turning Point Therapeutics; Financial Interests, Institutional, Invited Speaker: Genzyme Corporation, Hedera Dx, Medscape, MSD; Financial Interests, Institutional, Local PI: AbbVie, Amgen, Blueprint Medicines, Daiichi Sankyo, Pfizer, Roche-Genentech, Turning Point Therapeutics, Nuvalent, Enliven, Prelude therapeutics; Financial Interests, Institutional, Coordinating PI: AstraZeneca, OSE immunotherapeutics, Sanofi, Taiho; Financial Interests, Institutional, Steering Committee Member: BeiGene, GSK, Janssen, Takeda, Genmab; Financial Interests, Institutional, Funding: Cristal Therapeutics. S. Deshayes: Financial Interests, Institutional, Advisory Board: BMS, Janssen, AstraZeneca; Financial Interests, Institutional, Financially compensated role: Roche; Financial Interests, Institutional, Invited Speaker: AstraZeneca. C. Tissot: Financial Interests, Institutional, Advisory Board: Amgen, AstraZeneca, BMS, MSD, Roche, Sanofi; Financial Interests, Institutional, Invited Speaker: Amgen, Sandoz. B. Huret: Financial Interests, Institutional, Advisory Board: AstraZeneca, Sanofi, Roche; Financial Interests, Institutional, Invited Speaker: Chiesi, Menarini; Financial Interests, Institutional, Local PI: Amgen. M. Autheman: Financial Interests, Full or part-time Employment: Resilience. J. Mazieres: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Pierre Fabre, Takeda, BMS, MSD, Pfizer, Jiangsu Hengruii, Blueprint, Daiichi Sankyo, Novartis, Amgen; Financial Interests, Institutional, Funding: Illumina. All other authors have declared no conflicts of interest.